GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Total Long-Term Liabilities

Q32 Bio (Q32 Bio) Total Long-Term Liabilities : $70.61 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Q32 Bio Total Long-Term Liabilities?

Total Long-Term Liabilities includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities. Q32 Bio's Total Long-Term Liabilities for the quarter that ended in Mar. 2024 was $70.61 Mil.

Q32 Bio Total Long-Term Liabilities Historical Data

The historical data trend for Q32 Bio's Total Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Q32 Bio Total Long-Term Liabilities Chart

Q32 Bio Annual Data
Trend Dec21 Dec22 Dec23
Total Long-Term Liabilities
5.70 23.18 104.42

Q32 Bio Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Total Long-Term Liabilities Get a 7-Day Free Trial 23.18 - 26.94 104.42 70.61

Q32 Bio Total Long-Term Liabilities Calculation

Total Long-Term Liabilities represents the obiligation that incurred as part of normal operations that is expected to be repaid beyond the following twelve months or one business cycle, excluding minority interest. It includes Long-Term Debt & Capital Lease Obligation, PensionAndRetirementBenefit, NonCurrent Deferred Liabilities and Other Long-Term Liabilities.

Q32 Bio Total Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of Q32 Bio's Total Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Q32 Bio (Q32 Bio) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Q32 Bio Inc (NAS:QTTB) » Definitions » Total Long-Term Liabilities
Comparable Companies
Traded in Other Exchanges
N/A
Address
830 Winter Street, Waltham, MA, USA, 02451
Website
https://www.q32bio.com
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body's first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32's complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

Q32 Bio (Q32 Bio) Headlines

From GuruFocus

Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer

By PRNewswire • 04-03-2024